Together, these peptides target different pathways in the body, promoting comprehensive and efficient tissue repair
View source Michiko Kasuga, Kazuya Makita, Ken Ishitani, Kiyoshi Takamatsu, Kenji Watanabe, Gregory A Plotnikoff, et al
75 microg/kg) or saline placebo, administered via a subcutaneous injection every 3-days
Patented in 1998 (expired 2018), BPC-157 is also referred to as PL 14736, PL-10, or Bepecin in the scientific literature [3, 4, 5]
Solano, 2020
In pre-clinical models, BPC 157 has been observed to: Upregulate vascular endothelial growth factor (VEGF) , promoting new blood vessel formation in damaged tissue Modulate nitric oxide (NO) synthesis pathways, influencing vascular tone and healing cascades Interact with the growth hormone receptor system , potentially amplifying downstream tissue repair signaling Demonstrate cytoprotective effects along the gastrointestinal tract its native home territory as a gastric peptide Exhibit apparent neuroprotective properties in rodent models of CNS injury BPC 157 stability in gastric acid unusual for peptides has made it a focus of GI mucosal repair research